Listed for reference — companies are not ranked in any particular order.
| Market Size 2024 | US$ 1,051.4 Million |
| Market Size 2031 | US$ 2,163.7 Million |
| CAGR 2025–2031 | 10.9% |
| Segments | By Therapy Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors, Cancer Vaccines, Gene Therapy, Other Therapy Types) | By Indication (Blood Cancer, Lung Cancer, Breast Cancer, Colorectum Cancer, Prostate Cancer, Stomach Cancer, Cervical Cancer, Liver and Intrahepatic Bile Duct Cancer, Thyroid Cancer, Other Indications) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) | By End User (Hospital Pharmacies, Retail Pharmacies, Online Stores) |
| Geographies | Middle East(Turkiye, the United Arab Emirates, Saudi Arabia, Bahrain, Oman, Egypt, South Africa and Africa, Algeria, Nigeria, Kuwait, Qatar) |
| Deliverables | Historical analysis with CAGR · PEST & SWOT analysis · Market Size at Global, Regional, and Country Levels · Competitive heat map · Company profiles · Excel dataset |
| Report Code | BMIPUB00033508 |
| Lead Analyst | Krishna Sunthwal — Analyst, Research · View Profile |
Gain actionable insights with 211 pages of in-depth Middle East Cancer Targeted Therapy Market, including historical trends, 7-year market forecasts, SWOT analysis, competitive landscapes, and downloadable Excel datasets in a single comprehensive package.